Oral anticoagulation in XXXX .

@entity1 @entity64 @entity932 @entity548 @entity2067 @entity3926 @entity887 @entity3925 @entity5424 @entity955 @entity1229
@entity955 affects approximately 5 million @entity1 in the United States. The rate of @entity64 in adults with @entity955 depending on their risk factors varies between 1-20% annually. Anticoagulation with @entity2067 antagonists such as @entity1229 has been the mainstay therapy but it is cumbersome and requires close follow-up. Since 2010, three new oral anticoagulants have received Food and Drug Administration approval for @entity64 prevention in @entity955 . This review summarizes data from three landmark trials: RE-LY, ROCKET-AF, and ARISTOTLE. In addition, issues relating to cost, reversal, drug interactions, and perioperative discontinuation are discussed. Compared to @entity1229 , @entity3926 150mg twice daily lowered the primary outcome of @entity64 /systemic @entity887 by 34% (number needed to treat/yr 169) and had similar incidence of @entity548 . Rivaroxaban demonstrated non inferiority compared to the @entity1229 group for the primary outcome of @entity64 and systemic @entity887 and @entity548 . @entity5424 showed a relative risk reduction for the primary outcome of 21% (number needed to treat 300), and lowered @entity548 down by 31% (number needed to treat /yr 104). @entity5424 also showed a mortality benefit compared to @entity1229 (3.52 vs. 3.94%/year, p 0.047). All 3 oral anticoagulants lowered rates of @entity932 . The use of @entity3925 and @entity5424 has been projected to reduce medical costs when compared to @entity1229 , and @entity3926 is projected to have similar costs. All the 3 oral anticoagulants have robust randomized controlled trials supporting their comparability to @entity1229 therapy for @entity64 prevention in non @entity955 , with @entity5424 showing superiority in incidence of @entity64 , @entity548 and mortality.
